ClinConnect ClinConnect Logo
Search / Trial NCT05919511

Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease

Launched by INCYTE CORPORATION · Jun 16, 2023

Trial Information

Current as of July 09, 2025

Recruiting

Keywords

Chronic Graft Versus Host Disease C Gvhd Ma Gvhd 401 Thrive Gvhd Chronic Gvhd Allogenic Stem Cell Transplant (Allo Sct)

ClinConnect Summary

This clinical trial is looking at patients who have recently received an allogeneic stem cell transplant (a procedure where stem cells from a donor are used to replace damaged cells in a patient) and are at risk for developing chronic graft-versus-host disease (cGVHD). cGVHD is a condition where the donated cells attack the patient's body, which can lead to various health issues. The study aims to gather information about these patients to better understand how to manage and prevent cGVHD.

To participate in this study, individuals must be at least 18 years old and have had their stem cell transplant between 90 and 180 days prior to joining the trial. There are no specific exclusions, so many patients may be eligible. Participants will be asked to complete questionnaires about their health, either on their own or with some help. This study is currently recruiting, and your involvement could contribute to important research that may help other patients in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years inclusive at the time of signing the ICF
  • Allogeneic SCT 90 to 180 days prior to enrollment
  • Able to comprehend and willing to provide informed consent
  • Willing and able to complete participant-assessment questionnaires either alone or with minimal assistance from a caregiver and/or trained site personnel
  • Exclusion Criteria:
  • There are no exclusion criteria for this study

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for oncology and other serious diseases. With a commitment to advancing precision medicine, Incyte leverages its expertise in molecular biology and clinical research to develop targeted treatments that address unmet medical needs. The company is dedicated to improving patient outcomes through rigorous clinical trials and collaborations with healthcare professionals and research institutions. Incyte's robust pipeline includes a range of investigational therapies aimed at various cancers, showcasing its dedication to transforming the landscape of cancer treatment.

Locations

Chicago, Illinois, United States

Milwaukee, Wisconsin, United States

Rochester, Minnesota, United States

New York, New York, United States

Seattle, Washington, United States

Jacksonville, Florida, United States

New Orleans, Louisiana, United States

Duarte, California, United States

Birmingham, Alabama, United States

Atlanta, Georgia, United States

Orlando, Florida, United States

Nashville, Tennessee, United States

Baltimore, Maryland, United States

Chapel Hill, North Carolina, United States

Portland, Oregon, United States

Salt Lake City, Utah, United States

Los Angeles, California, United States

Phoenix, Arizona, United States

Charlotte, North Carolina, United States

Dallas, Texas, United States

Columbus, Ohio, United States

Fairway, Kansas, United States

Danville, Pennsylvania, United States

Grand Rapids, Michigan, United States

Boston, Massachusetts, United States

New Brunswick, New Jersey, United States

Aurora, Colorado, United States

Chicago, Illinois, United States

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported